Cargando…

P1745: ADHERENCE TO TREATMENT OF HEMATOLOGICAL MALIGNANCIES PATIENTS WITH ANXIETY AND DEPRESSION

Detalles Bibliográficos
Autores principales:	Vybornykh, D. E., Moiseeva, T., Gemdzhian, E., Gaponova, T., Novikova, D.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2022
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9428963/ http://dx.doi.org/10.1097/01.HS9.0000849836.87141.59

Ejemplares similares

PB2700: ANXIETY AND DEPRESSION IN HEMATOLOGICAL MALIGNANCIES PATIENTS: FOCUS ON TREATMENT ADHERENCE
por: Vybornykh, Dmitry E, et al.
Publicado: (2023)

Electronic inventions: 1745-1976
por: Dummer, Geoffrey William Arnold
Publicado: (1977)

De Aneurysmatibus. The Latin Text of Rome, 1745
por: Gray, Frank D.
Publicado: (1954)

P1712: CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS
por: Güven, Z., et al.
Publicado: (2022)

P1574: ANTINEOPLASTIC THERAPY FOR HEMATOLOGIC MALIGNANCIES DURING COVID-19
por: Chudnova, T., et al.
Publicado: (2022)

P1700: EARLY APPEARANCE OF CARDIOTOXICITY, IN CHILDREN WITH HEMATOLOGICAL MALIGNANCIES (HM)
por: Antoniadi, K., et al.
Publicado: (2022)

Depression and anxiety in patients with hematological malignancies, prevalence, and associated factors
por: Abuelgasim, Khadega A., et al.
Publicado: (2016)

P1599: THERAPY AND HOSPITAL MORTALITY PREDICTORS IN PATIENTS WITH LYMPHOPROLIFERATIVE DISORDERS AND CONCOMITANT COVID-19 INFECTION
por: Polyakov, Y., et al.
Publicado: (2022)

P1593: IMMUNE BIOMARKERS TO PREDICT SARS-COV-2 VACCINE EFFECTIVENESS IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Tamariz-Amador, L.-E., et al.
Publicado: (2022)

P1574: EFFICACY AND SAFETY OF TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN PATIENTS WITH HEMATOLOGICAL MALIGNANCIES
por: Aleshina (Gavrilina), Olga, et al.
Publicado: (2023)

1745P SARS-CoV-2 infects metabolically-primed epithelial cells in lung cancer models
por: Cargill, K.R., et al.
Publicado: (2020)

P1557: A STUDY ON THE IMMUNOGENICITY OF COVID-19 VACCINE IN PATIENTS WITH HEMATOLOGIC MALIGNANCY
por: Mesina, Flordeluna, et al.
Publicado: (2023)

La familia en la provincia de Venezuela, 1745-1798.
por: Almécija B., Juan 1949-
Publicado: (1992)

P1590: OUTCOME OF HYPERBARIC OXYGEN THERAPY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES –A TERTIARY CANCER CENTER EXPERIENCE
por: Kim, K., et al.
Publicado: (2022)

P1109: TRIAL IN PROGRESS: PHASE 1B/2 TRIAL OF TAZEMETOSTAT IN COMBINATION WITH VARIOUS TREATMENTS IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Bessudo, A., et al.
Publicado: (2022)

P1351: CHARACTERIZING ALLOGENEIC STEM CELL TRANSPLANTATION SAFETY IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES AFTER PEMBROLIZUMAB THERAPY
por: Kuruvilla, J., et al.
Publicado: (2022)

Outcome in severe sepsis and septic shock patients with hematological malignancies: impact of recent intravenous chemotherapeutic treatment
por: Vandijck, D, et al.
Publicado: (2008)

Outcomes of patients with hematologic malignancies admitted to the ICU
por: Duayer, I, et al.
Publicado: (2015)

The Scottish poor law. Its operation in the north-east from 1745 to 1845
Publicado: (1977)

PB1745: SURVIVAL AND PROGNOSTIC FACTORS OF PEDIATRIC ACUTE LYMPHOBLASTIC LEUKEMIA IN OMAN.
por: Almamari, Moza, et al.
Publicado: (2023)

P1543: CHARACTERISTICS AND OUTCOMES OF PATIENTS WITH HEMATOLOGICAL MALIGNANCIES THAT NEED VASOACTIVE SUPPORT – SINGLE CENTER STUDY
por: Vitkon, Roy, et al.
Publicado: (2023)

Sepsis and neutropenia in hematological malignancies
por: Labiad, Y, et al.
Publicado: (2014)

P1721: PROGNOSTIC FACTORS IN PATIENTS IN THE TERMINAL PHASE OF HEMATOLOGICAL MALIGNANCIES WHO RECEIVED HOME MEDICAL CARE
por: Miyashita, N., et al.
Publicado: (2022)

P1723: A FEASIBILITY STUDY OF PEER SUPPORT IN FAMILY CAREGIVERS OF PATIENTS NEWLY DIAGNOSED WITH HEMATOLOGIC MALIGNANCY
por: Nielsen, I. H., et al.
Publicado: (2022)

Anxiety and Depression of the Patients with Hematological Malignancies during Hospitalization for Hematopoietic Stem Cell Transplantation
por: Seo, Ho-Jun, et al.
Publicado: (2019)

P1592: MATCHED CONTROL COMPARISON OF SURVIVAL OF HOSPITALIZED COVID-19 PATIENTS WITH HEMATOLOGICAL MALIGNANCIES, DATA FROM A LARGE TERTIARY CENTER REGISTRY
por: Lucijanic, M., et al.
Publicado: (2022)

P1568: EARLY, BUT NOT LATE USE OF REMDESVIR AND CONVALESCENT PLASMA REDUCES MORTALITY OF COVID 19 IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES – A STUDY OF KROHEM
por: Aurer, I., et al.
Publicado: (2022)

P1577: RISK FACTORS FOR MORTALITY IN CRITICALLY ILL PATIENTS WITH HEMATOLOGICAL MALIGNANCIES IN A POLYVALENT INTENSIVE CARE UNIT: A RETROSPECTIVE STUDY
por: Dias, A. R., et al.
Publicado: (2022)

P1588: A SINGLE CENTER COMPARATIVE CLINICAL ANALYSIS OF THE SARS-COV-2 INFECTION BEFORE AND AFTER VACCINATION IN PATIENTS DIAGNOSED WITH HEMATOLOGIC MALIGNANCIES
por: Jiménez, M., et al.
Publicado: (2022)

PIV-21 Respiratory viral infections in adult patients with hematologic malignancies
por: Bayram, A., et al.
Publicado: (2009)

Is admission of hematologic malignancies in the ICU justified?
por: Gasparovic, VG, et al.
Publicado: (2015)

Outcomes of Breakthrough COVID-19 Infections in Patients with Hematologic Malignancies
por: Chien, Kelly S., et al.
Publicado: (2022)

P1551: INCIDENCE AND PREDICTORS FACTORS FOR 30-DAY UNPLANNED HOSPITAL READMISSION AMONG HEMATOLOGIC MALIGNANT DISEASE PATIENTS
por: LI, Xiao, et al.
Publicado: (2023)

P871: ISB 1442, A FIRST-IN-CLASS CD38 AND CD47 BISPECIFIC ANTIBODY INNATE CELL MODULATOR FOR THE TREATMENT OF CD38 POSITIVE HEMATOLOGICAL MALIGNANCIES
por: Grandclement, C., et al.
Publicado: (2022)

P1339: IMPACT OF CLONAL HEMATOPOIESIS AND CANAKINUMAB ON NON-HEMATOLOGICAL MALIGNANCY: ANALYSIS OF THE CANTOS RANDOMIZED CLINICAL TRIAL
por: Woo, Janghee, et al.
Publicado: (2023)

P1733: NON-HEMATOLOGICAL MALIGNANCIES IN IDIOPATHIC MULTICENTRIC CASTLEMAN DISEASE PATIENTS: A MATCHED COHORT ANALYSIS USING A HEALTH CLAIMS-BASED DATASET
por: Mukherjee, S., et al.
Publicado: (2022)

P1608: EXPERIENCE AND COMPLICATIONS WITH THE USE OF PICCS IN HEMATOLOGIC PATIENTS
por: Sanchez-Paz, L., et al.
Publicado: (2022)

Early risk stratification in patients with oncological and hematological malignancies in the emergency department
por: Rast, A, et al.
Publicado: (2014)

P1121: TAKEAIM LYMPHOMA- AN OPEN-LABEL, DOSE ESCALATION AND EXPANSION TRIAL OF EMAVUSERTIB (CA-4948) IN COMBINATION WITH IBRUTINIB IN PATIENTS WITH RELAPSED OR REFRACTORY HEMATOLOGIC MALIGNANCIES
por: Joffe, E., et al.
Publicado: (2022)

Biofilm formation and antagonistic activity of Lacticaseibacillus rhamnosus (PTCC1712) and Lactiplantibacillus plantarum (PTCC1745)
por: Rezaei, Zeinab, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_jnd6vge0bmhc4pq616t21vmh4m